Semaglutide, tirzepatide, retatrutide and the wider metabolic research space.
This is the thing in metabolic pharmacology I find hardest to square. Tirzepatide includes GIP receptor agonism and works. There's separately credible work suggesting GIP receptor…
A lot of the confusion in this category comes from reading summaries instead of papers, so here's what I look at, in order. 1. The analysis population. Intention to treat vs compl…
Comparing published protocols, the escalation intervals differ in ways that don't obviously track half life. Curious whether that's tolerability driven or just historical.
Amylin is co-secreted with insulin and has its own role in satiety and gastric emptying. Analogs are being developed alone and combined with GLP-1 agents. Why I think it's underra…
keeps changing and i cant find one thats current. registries are accurate but impossible to read as an overview
these get discussed like theyre different drugs and i dont think thats the right frame. the molecule can be the same. what differs is the pathway: an approved product has a review…
GLP-1 agonist means an agonist at the GLP-1 receptor. Semaglutide is one. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple. Calling those "GLP-1s" is like calling …
Everyone quotes the efficacy numbers. Almost nobody quotes what happens after stopping. The published withdrawal and extension data across this class shows substantial regain afte…
Peptides get destroyed in the gut, which is why almost everything in this space is injected. Getting an oral version to work is a real pharma achievement, not a formulation conven…
There is no direct head to head between these. Every comparison you see is cross-trial. Cross-trial comparison is unreliable for boring but decisive reasons: different populations…
This comparison gets made constantly and the single most important fact usually gets buried. Tirzepatide is approved for specific indications and has completed phase 3. Retatrutid…
Most asked comparison on the whole forum so worth getting right. Mechanism: semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist, GLP-1 plus GIP. That second rec…
Discussions are educational and cover published research. Nothing here is individualised medical advice.